PF-05082566
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for PF-05082566, covering 2018-10-11 to 2022-10-19. Get the full timeline:
Most recent: Clinical Trial Update: 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer [Phase 1]